|
A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation
RECRUITINGPhase 2Sponsored by Genfleet Therapeutics (Shanghai) Inc.
Actively Recruiting
PhasePhase 2
SponsorGenfleet Therapeutics (Shanghai) Inc.
Started2026-08-20
Est. completion2028-08-31
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07784374
Summary
This is a phase 2 study. All subjects are patients with locally advanced unresectable or metastatic pancreatic cancer harboring KRAS G12D mutation who have received at least one prior line of systemic therapy. The purpose of this study is to evaluate the anti-tumor efficacy of GFH375 plus GFH276 versus GFH375 monotherapy, and to assess the impact of GFH375 plus GFS202A versus GFH375 monotherapy on patient body weight.
Eligibility
Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria: * Able to provide written informed consent prior to any study-related procedures. * Male or female subjects aged between 18 and 80 years (inclusive) at the time of informed consent. * Histologically or cytologically confirmed pancreatic adenocarcinoma. * Estimated life expectancy ≥ 3 months as judged by the investigator. * Has received at least 1 prior line of systemic anti-tumor therapy. * Has at least one measurable lesion per RECIST version 1.1. * Adequate organ function. Exclusion Criteria: * Other malignancy that has progressed or required treatment within 3 years prior to study entry. * Active central nervous system (CNS) metastases. * Prior treatment with KRAS G12D-specific or pan-RAS/KRAS targeted agents. * Clinically significant severe cardiovascular disease. * Stroke or other severe cerebrovascular events within 6 months prior to randomization. * Significant acute or chronic infectious disease. * Severe psychiatric disorder, history of drug abuse, or significant alcohol abuse. * Pregnant or lactating female subjects. * Other conditions that, in the investigator's opinion, make the subject unsuitable for study participation.
Conditions2
CancerPancreatic Cancer
Interventions3
Related trials
- A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation — Genfleet Therapeutics (Shanghai) Inc.
- A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations — Genfleet Therapeutics (Shanghai) Inc.
- A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation — Genfleet Therapeutics (Shanghai) Inc.
- Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer — Genfleet Therapeutics (Shanghai) Inc.
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorGenfleet Therapeutics (Shanghai) Inc.
Started2026-08-20
Est. completion2028-08-31
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07784374